Thus, the combination of GnRHa and rhGH enhances the GH-IGF-1 axis, maximizing height gain in CPP patients with severe growth deceleration or very poor PAH after GnRHa treatment. The gene discussed is GH1; the disease is pulmonary arterial hypertension.